Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supaglutide + metformin in type 2 diabetes mellitus (post-metformin inadequate control)
CTR20211312Phase 3Completed
- Sponsor
- Yinno Pharma
- Start
- Jul 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of efsubaglutide alfa in type 2 diabetes mellitus (T2DM), sponsored by Yinno Pharma. Started Jul 2021; status: completed.
02
Drugs
efsubaglutide alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20211312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211312.